سعر سوتنت 50 مجم 28 كبسولة 2024

Sunitinib (as malate) 50 mg oral capsules, multi-targeted receptor tyrosine kinase inhibitor by Pfizer; pack of 28 capsules.

• Gastrointestinal stromal tumour (GIST) after disease progression on or intolerance to imatinibPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Advanced renal cell carcinoma (RCC)Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjuvant treatment of adults at high risk of recurrent RCC following nephrectomyPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=25%): fatigue/asthenia, diarrhoea, mucositis/stomatitis, nausea, decreased appetite, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding, dysgeusia, dyspepsia and thrombocytopenia.International label, same product · DailyMed (U.S. National Library of Medicine)

• None stated in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: hepatotoxicity, which may be severe and in some cases fatal; monitor hepatic function and interrupt, reduce or discontinue as recommended.International label, same product · DailyMed (U.S. National Library of Medicine)
• Cardiovascular events (myocardial ischaemia/infarction, heart failure, cardiomyopathy, decreased LVEF), QT prolongation/torsade de pointes, hypertension and haemorrhagic events (including fatal tumour haemorrhage and viscus perforation) have occurred.International label, same product · DailyMed (U.S. National Library of Medicine)
• Hypoglycaemia, osteonecrosis of the jaw and impaired wound healing: check glucose regularly; withhold at least 3 weeks before invasive dental procedures or elective surgery.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitorsAvoid; if unavoidable reduce sunitinib to a minimum of 37.5 mg daily (GIST/RCC) or 25 mg daily (pNET).DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducersAvoid; if unavoidable consider increasing the sunitinib dose as per label maximums.DailyMed (U.S. National Library of Medicine)

• Advise not to breastfeed during treatment and for at least 4 weeks after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Sunitinib (as malate): Inhibits multiple receptor tyrosine kinases including PDGFR, VEGFR, KIT, FLT3, CSF-1R and RET (US label).